# Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder

> **NCT01414114** · PHASE2 · COMPLETED · sponsor: **KAI Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Secondary Hyperparathyroidism

## Interventions

- **DRUG:** Etelcalcetide

## Key facts

- **NCT ID:** NCT01414114
- **Lead sponsor:** KAI Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12-05
- **Primary completion:** 2012-05-21
- **Final completion:** 2012-05-21
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2017-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01414114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01414114, "Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mineral and Bone Disorder". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01414114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*